BioVie shares are trading higher after the company announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.

Benzinga Newsdesk www.benzinga.com Positive 94.3%

Neg 0% Neu 0% Pos 94.3%

Comments

No comments yet. Be the first!